1. Home
  2. CGON vs SWI Comparison

CGON vs SWI Comparison

Compare CGON & SWI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CGON
  • SWI
  • Stock Information
  • Founded
  • CGON 2010
  • SWI 1999
  • Country
  • CGON United States
  • SWI United States
  • Employees
  • CGON N/A
  • SWI N/A
  • Industry
  • CGON
  • SWI Computer Software: Prepackaged Software
  • Sector
  • CGON
  • SWI Technology
  • Exchange
  • CGON NYSE
  • SWI Nasdaq
  • Market Cap
  • CGON 2.3B
  • SWI 2.4B
  • IPO Year
  • CGON 2024
  • SWI 2009
  • Fundamental
  • Price
  • CGON $27.85
  • SWI $18.32
  • Analyst Decision
  • CGON Strong Buy
  • SWI Hold
  • Analyst Count
  • CGON 10
  • SWI 5
  • Target Price
  • CGON $65.11
  • SWI $17.60
  • AVG Volume (30 Days)
  • CGON 430.1K
  • SWI 1.4M
  • Earning Date
  • CGON 03-04-2025
  • SWI 02-12-2025
  • Dividend Yield
  • CGON N/A
  • SWI 5.46%
  • EPS Growth
  • CGON N/A
  • SWI N/A
  • EPS
  • CGON N/A
  • SWI 0.64
  • Revenue
  • CGON $684,000.00
  • SWI $796,895,000.00
  • Revenue This Year
  • CGON $158.34
  • SWI $3.09
  • Revenue Next Year
  • CGON N/A
  • SWI $4.16
  • P/E Ratio
  • CGON N/A
  • SWI $28.63
  • Revenue Growth
  • CGON 258.12
  • SWI 5.03
  • 52 Week Low
  • CGON $25.77
  • SWI $10.14
  • 52 Week High
  • CGON $47.78
  • SWI $18.55
  • Technical
  • Relative Strength Index (RSI)
  • CGON 41.49
  • SWI 84.88
  • Support Level
  • CGON $27.10
  • SWI $18.27
  • Resistance Level
  • CGON $29.42
  • SWI $18.36
  • Average True Range (ATR)
  • CGON 1.15
  • SWI 0.17
  • MACD
  • CGON -0.10
  • SWI 0.13
  • Stochastic Oscillator
  • CGON 29.02
  • SWI 94.20

About CGON CG ONCOLOGY INC

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

About SWI SolarWinds Corporation

SolarWinds Corp is a provider of information technology (IT), and management software. Company offers full-stack observability solutions. The company's business is focused on building products that enable technology professionals and leaders to securely monitor and manage the performance of their IT environments, whether on-premises, in the cloud or in hybrid deployments. The products offered are designed to monitor and manage networks, systems, databases and applications across on-premises, multi-cloud and hybrid IT environments without the need for customization or professional services.

Share on Social Networks: